



November 16, 2022

Nippon Kayaku Co., Ltd.,
Celltrion Healthcare Japan, K.K.,

**Launch in Japan of Bevacizumab BS for I.V. Infusion 100mg•400mg
“CTNK” ,an anti-VEGF humanized monoclonal antibody**

Tokyo, Japan, November 16, 2022, Nippon Kayaku Co., Ltd. (Head Office: Tokyo; President: Atsuhiro Wakumoto; hereinafter referred to as “Nippon Kayaku”) and Celltrion Healthcare Japan Co., Ltd. (Head Office: Tokyo; President: Hogun.Kim; hereinafter referred to as “Celltrion”) today announced that Nippon Kayaku has launched the sale of Bevacizumab BS for I.V. Infusion 100mg•400mg “CTNK” (hereinafter referred to as “Bevasizumab BS “CTNK”).

Bevacizumab BS “CTNK” is a biosimilar of the Bevacizumab that is a monoclonal antibody (a type of protein) that has been designed to recognize and attach to vascular endothelial growth factor (VEGF), a protein that circulates in the blood and makes blood vessels grow. In this September, Nippon Kayaku obtained the manufacture and marketing approval with the indication of unresectable advanced or recurrent colorectal cancer, unresectable advanced or recurrent non-squamous non-small cell lung cancer and inoperable or recurrent breast cancer.

Nippon Kayaku and Celltrion will strive to promote the proper use of this drug, provide information, and ensure a stable supply. In addition, we will promote the domestic development of biosimilars and strive to contribute to patients, their families, and medical professionals.

[Please direct inquiries regarding this matter to:]

Telephone: +81-3-6731-5237

Corporate Communications Division

Nippon Kayaku Co., Ltd.

Telephone: +81-3-6260-6840

Celltrion Healthcare Japan, K.K.,